$450,000.00 in Sales Expected for Arcadia Biosciences Inc (NASDAQ:RKDA) This Quarter

Equities analysts expect that Arcadia Biosciences Inc (NASDAQ:RKDA) will report $450,000.00 in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Arcadia Biosciences’ earnings, with the lowest sales estimate coming in at $400,000.00 and the highest estimate coming in at $500,000.00. Arcadia Biosciences posted sales of $440,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 2.3%. The company is expected to announce its next quarterly earnings report on Wednesday, March 25th.

On average, analysts expect that Arcadia Biosciences will report full year sales of $1.15 million for the current fiscal year, with estimates ranging from $1.10 million to $1.20 million. For the next financial year, analysts expect that the company will report sales of $8.55 million, with estimates ranging from $6.30 million to $10.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Arcadia Biosciences.

Arcadia Biosciences (NASDAQ:RKDA) last issued its quarterly earnings results on Wednesday, November 6th. The basic materials company reported ($2.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($1.27). The company had revenue of $0.39 million during the quarter, compared to analyst estimates of $0.31 million. Arcadia Biosciences had a negative net margin of 1,938.76% and a negative return on equity of 198.10%.

Several equities analysts recently issued reports on the company. ValuEngine cut Arcadia Biosciences from a “sell” rating to a “strong sell” rating in a research report on Wednesday, November 27th. HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Arcadia Biosciences in a research report on Monday. Finally, National Securities boosted their price target on Arcadia Biosciences from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, August 15th.

In other Arcadia Biosciences news, Director Kevin Comcowich bought 15,000 shares of the company’s stock in a transaction on Tuesday, September 10th. The shares were bought at an average price of $6.49 per share, for a total transaction of $97,350.00. Following the transaction, the director now owns 5,000 shares of the company’s stock, valued at approximately $32,450. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have acquired a total of 32,200 shares of company stock worth $188,076 in the last quarter. 3.30% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RKDA. Citadel Advisors LLC acquired a new stake in Arcadia Biosciences in the 2nd quarter valued at $32,000. Cambridge Investment Research Advisors Inc. bought a new position in shares of Arcadia Biosciences during the second quarter worth about $34,000. Squarepoint Ops LLC bought a new position in shares of Arcadia Biosciences during the third quarter worth about $124,000. Sabby Management LLC lifted its position in shares of Arcadia Biosciences by 150.0% during the third quarter. Sabby Management LLC now owns 50,000 shares of the basic materials company’s stock worth $234,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Arcadia Biosciences by 47.1% during the second quarter. Vanguard Group Inc. now owns 117,059 shares of the basic materials company’s stock worth $359,000 after purchasing an additional 37,472 shares during the last quarter. Institutional investors own 8.03% of the company’s stock.

RKDA stock traded up $0.21 during trading on Friday, hitting $5.42. The company had a trading volume of 172,571 shares, compared to its average volume of 1,262,908. The firm has a market cap of $45.15 million, a PE ratio of -1.01 and a beta of -2.98. Arcadia Biosciences has a 1-year low of $1.82 and a 1-year high of $10.40. The firm has a 50-day moving average price of $4.76 and a 200-day moving average price of $4.68. The company has a quick ratio of 5.27, a current ratio of 5.58 and a debt-to-equity ratio of 0.11.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.

Read More: What are the economic characteristics of a bear market?

Get a free copy of the Zacks research report on Arcadia Biosciences (RKDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.